I
103D CONGRESS
2D SESSION
H. R. 5222
To provide for nonanimal acute toxicity testing by the Federal Government.
IN THE HOUSE OF REPRESENTATIVES
OCTOBER 6, 1994
Mr. LANTOS (for himself, Mr. ACKERMAN, Mr. BEILENSON, Mr. BROWN of
California, Mr. DEFAZIO, Mr. DELLUMS, Mr. GEJDENSON, Mr. HAM-
BURG, Mr. HOCHBRUECKNER, Mr. JOHNSON of South Dakota, Mr.
JOHNSTON of Florida, Mr. KLECZKA, Mr. MANTON, Mr. MINETA, Mr.
MORAN, Mr. NEAL of Massachusetts, Mr. RAVENEL, Ms. ROYBAL-AL-
LARD, Mr. SHAYS, Mr. SWETT, Mr. SWIFT, and Mr. TOWNS) introduced
the following bill; which was referred to the Committee on Energy and
Commerce
A BILL
To provide for nonanimal acute toxicity testing by the
Federal Government.
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ‘‘Consumer Products
Safe Testing Act’’.
SEC. 2. FINDINGS AND POLICY.
(a) FINDINGS.—The Congress finds that—
(1) nonanimal acute toxicity tests have been de-
veloped in recent years that have shown a level of re-
liability sufficient for the reduction or replacement
of animal acute toxicity tests such as the Draize test
for many products regulated by the Federal Govern-
ment;
(2) many manufacturers have found nonanimal
acute toxicity tests to be adequate for evaluating the
safety of products for the purposes of complying
with Federal regulations or guidelines;
(3) the Federal Government has discouraged
the use of these alternatives through regulations
that mandate or encourage the use of animal acute
toxicity tests, or by not prescribing other, less costly,
more accurate and humane alternatives;
(4) many manufacturers are reluctant to use
nonanimal tests without encouragement from the
Federal Government; and
(5) private industry and the consumer will ben-
efit from the promotion of alternative methods of
testing when these alternatives are as accurate and
more humane than animal tests.
(b) POLICY.—Federal departments and agencies shall
encourage the development and use of product testing pro-
cedures that accurately reflect the acute health effects on
SEC. 4. APPLICATION.
This Act shall not apply to regulations, guidelines,
or recommendations related to medical research.
SEC. 5. DEFINITIONS.
For purposes of this Act:
(1) ANIMAL.—The term ‘‘animal’’ means any
vertebrate.
(2) ANIMAL ACUTE TOXICITY TEST.—The term
‘‘animal acute toxicity test’’ means an acute toxicity
test on animals, including (but not limited to) the
Draize eye or skin irritancy test, LD–50 test, ap-
proximate lethal dose test, and the limit test.
(3) 
FEDERAL
DEPARTMENT
OR
AGENCY
HEAD.—The term ‘‘Federal department or agency
head’’ means the head of a Federal department or
agency who—
(A) has authority to promulgate regula-
tions, guidelines, and recommendations with re-
spect to procedures to be used in the safety
testing by manufacturers of products, including
consumer products, veterinary products, and
products containing hazardous or toxic sub-
stances; or
(B) licenses or approves products, labeling
requirements or the transportation of products
based on the results of these tests.
(4) MEDICAL RESEARCH.—The term ‘‘medical
research’’ means research related to the causes, di-
agnosis, treatment, or control of physical or mental
impairments of humans or animals. The term does
not include the testing of a product to determine its
toxicity for the purpose of complying with protocols,
recommendations, or guidelines for testing required,
recommended, or accepted by a Federal regulatory
agency for a product introduced in commerce.
(5) NONANIMAL ACUTE TOXICITY TEST.—The
term ‘‘nonanimal acute toxicity test’’ means an
acute toxicity test not conducted on animals. Such
tests include (but are not limited to) cell culture,
computer 
modeling, 
protein 
alteration, 
and
chorioallantoic membrane techniques.
Æ